Summary and Conclusion

Slides:



Advertisements
Similar presentations
SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease.
Advertisements

Slide 1 PERSEUS Primary Endpoint Dean Kereiakes ACC/i2 Late Breaking Trial Monday, March 15, 2010, 11:06 am TAXUS PERSEUS A Novel Platinum Chromium, Thin-Strut.
Www. Clinical trial results.org The C-SIRIUS Study A The Canadian Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Eluting Stent in the Treatment.
Complex Lesion Subsets: Indications for DES Andreas Baumbach, MD, FRCP, FESC Bristol Heart Institute.
3rd CEEGI Advisory Board1 Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac.
Meredith ● EVOLVE Primary Endpoint ● TCT 2011 ● San Francisco, CA Slide 1 Meredith ● EVOLVE overview ● TCT 2010 ● Washington, DC Slide 1 Clinical and Angiographic.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
1 of Presented by Gregg W. Stone, MD, ACC PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
A Randomized Comparison of Everolimus-­ Eluting Absorb Bioresorbable Vascular Scaffolds vs. Everolimus-Eluting Metallic Stents: One-Year Angiographic and.
TAXUS Landmark Analysis Impact of Long-Term Clopidogrel Usage on Death, Myocardial Infarction and Stent Thrombosis Gregg W. Stone, MD Stephen G. Ellis,
TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.
Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Early and Late Stent Thrombosis Rates in 5,054 Real-World Patients from XIENCE V USA With and Without Dual Antiplatelet Therapy Interruptions James Hermiller,
The REVA Tyrosine-Derived Polycarbonate Bioresorbable Scaffold: Long-term Outcomes Using Multimodality Imaging Greg L. Kaluza, MD, PhD, FACC Director of.
Late Clinical Outcomes after Bioresorbable or Permanent Polymer Everolimus-Eluting Stents: 2-Year Results from the EVOLVE II Randomized Trial Dean J.
Two-Year Outcomes in Real-World Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus US Post-Approval.
Background & Study Design
Martin B. Leon, MD Key Messages Tryton Pivotal: Randomized Trial and
Outcomes in the CoreValve US High-Risk Pivotal Trial in Patients with a Society of Thoracic Surgeons Predicted Risk of Mortality Less than or Equal to.
Novel Trial Design Focus - Left Main and “All Comers” DES Studies: All-Comers Studies. Interventional View Jeffrey J. Popma, MD Director, Innovations in.
Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Vivek Y. Reddy.
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Disclosures Runlin Gao has received a research grant
Boston Scientific Corporation: DES Bioabsorbable Technologies
Runlin Gao, M.D. On behalf of ABSORB China Investigators
Two-year clinical outcomes in the EVOLVE FHU trial: A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Ian Meredith.
Three-year results from the multicentre PROMUS Element European Post-Approval (PE-Prove) Registry: outcomes in 1010 unselected patients treated with a.
First Report of Three-Year Outcomes With the Repositionable and Fully Retrievable Lotus™ Aortic Valve Replacement System: Results From the REPRISE I.
BRS Next Large Trials: What is on the Horizon?
PLATINUM Long Lesion 12-Month Outcomes
Final Five-Year Outcomes Following Implantation of the Promus Element® Platinum Chromium Everolimus-Eluting Stent in De Novo Coronary Artery Lesions in.
Gregg W. Stone, MD Columbia University Medical Center
ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.
The Tryton Bifurcation Trial:
CoreValve Continued Access Study Shows Continued Improvement in 1-Year Outcomes With Self-Expanding Transcatheter Aortic Valve Replacement Steven J. Yakubov,
Greg L. Kaluza, MD, PhD, FACC Cardiovascular Research Foundation
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
for the PLATINUM SV Investigators
DES Should be Used as the Default Stent in ACS!
The XIENCE V EXCEED Study
OCT-Guided PCI What needs to be done to establish criteria?
The SYNERGY™ Biodegradable Program & EVOLVE Clinical Trials
Dynamic Mitral Valve Ring Annuloplasty: Micardia Concept
MACE Trial Rationale, Study Design, and Current Status
The Guidelines Should Be Change!
PLATINUM Long Lesion 12-Month Outcomes
on behalf of the ABSORB II Investigators
Stenting of Coronary Arteries in Non Stress/Benestent Disease
REALITY: 8 month results
How and why this study may change my practice ?
EVERBIO II Trial design: Patients with CAD were randomized in a 1:1:1 fashion to either Absorb BVS, Biomatrix Flex stent [BES], or Promus Element EES.
3-Year Clinical Outcomes From the RESOLUTE US Study
for the SPIRIT IV Investigators
Presented at ACC 2003 Late Breaking Clinical Trials
Randomized Comparison in the Setting of Acute MI
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
A Prospective, Randomized Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial Gregg W. Stone, Paul S. Teirstein,
STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.
for the SPIRIT IV Investigators
ENDEAVOR II Five-Year Clinical Follow-up
TAXUS – Myonecrosis and sidebranch patency concerns are short-term issues with no long-term consequences, and the benefits are undeniable Jeffrey J. Popma,
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
Gregg W. Stone, MD Columbia University Medical Center
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Updated 3-Year Meta-Analysis of the TAXUS Clinical Trials Safety and Efficacy Demonstrated in 3,445 Randomized Patients Time allocation for this talk.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.
Atlantic Cardiovascular Patient Outcomes Research Team
Presentation transcript:

Summary and Conclusion Stent Design Impacts Geometric Vessel Distortion Following Coronary Artery Stenting in Severely Angulated Lesions: Angiographic Analysis of the PLATINUM Trial Jeffrey J. Popma, MD1, Alexandra Almonacid, MD1, Dean J. Kereiakes, MD2, Ian T. Meredith, AM, MBBS, PhD3, Paul S. Teirstein, MD4, Dominic J. Allocco, MD5, Keith D. Dawkins, MD5, Gregg W. Stone, MD6 1. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; The Christ Hospital Heart and Vascular Center/The Lindner Center for Research and Education at The Christ Hospital;, Cincinnati OH 3. MonashHEART, Southern Health, Monash Medical Centre, Clayton, Victoria, Australia; 4. Scripps Clinic, Division of Cardiovascular Diseases, La Jolla, CA; 5. Boston Scientific Corporation, Marlborough, MA 6. Columbia University Medical Center / New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY Poster presented at ACC 2013, March 9, 2013. Results Figure 1. Pre- and Post-procedure Examples of Change in Curvature and Angulation Background A Example #1 Baseline demographics and cardiac history were generally similar between patients in the CoCr-ESS and PtCr-EES arms of this PLATINUM vessel straightening analysis (data not shown). Lesion length was significantly longer in the PtCr-EES group compared to CoCr-EES (CoCr 12.4±5.7 vs PtCr15.2±6.2, P=0.02). The average vessel bend at baseline was 79 degrees in both groups (Table). Use of an unplanned stent for bailout or unsuccessful study stent placement was significantly more common with CoCr-EES vs PtCr (28.0% vs 8.2%, P=0.01), as was treatment with multiple stents (18.0% vs 4.0%, P=0.03). The change in angulation (degrees) from pre- to post-procedure was significantly lower in patients treated with PtCr-EES compared to CoCr-EES (Table). The curvature difference from pre- to post-procedure was numerically lower with the PtCr-EES but this did not reach significance (Table). An analysis excluding patients with multiple stents was performed in order to isolate the effect of stent design. Similar results to the overall analysis were found (Table). Distortion of native vessel geometry after coronary stenting has been associated with reduced coronary flow velocity and shear stress, increased stent fracture, impaired vessel healing, and late restenosis. Greater stent conformability may minimize vessel distortion and improve early and late coronary flow. This analysis examines the impact of stent design on vessel straightening in severely angulated lesions. Maximum Minimum Methods Pre-procedure Post-procedure Pre-procedure Post-procedure Curvature Angulation B Example #2 The PLATINUM trial randomized 1530 patients with 1 or 2 de novo native coronary artery lesions (baseline RVD≥2.50 mm to ≤4.25 mm and length ≤24 mm) to receive the CoCr-EES (XIENCE V; Abbott Vascular) or the PtCr-EES (PROMUS Element; Boston Scientific). Lesions were to be treated with a single planned stent. For XIENCE V, available stent sizes were 12, 18 and 28 mm; for PROMUS Element, stent sizes were 12, 20 and 28 mm. A post hoc angiographic analysis of the 100 (N=50 CoCr-EES, N=50 PtCr-EES) most severely angulated lesions (those with the highest baseline bend) was conducted. Vessel angulation (degrees) and curvature (mm-1) immediately before and after stent implantation were measured by a blinded, independent angiographic core laboratory using three dimensional quantitative angiographic software (CAAS V5.10 QCA, Pie Medical Imaging, The Netherlands). Minimum and maximum angulation and curvature were measured and correspond to end-diastole and end-systole, respectively. Table. Vessel Straightening Analysis Factor CoCr-EES PtCr-EES P value All Lesions N= 50 N=50 Stent Length, mm 19.4±10.4 22.0±7.5 0.16 Baseline Bend, degrees (at min MLD) 79.1±13.5 79.0±11.7 0.97   Min Max Pre-procedure Angulation, degrees 80.5±22.9 97.0±24.8 76.0±24.0 91.2±25.9 0.33 0.26 Post-procedure Angulation, degrees 55.4±27.1 65.1±30.4 60.5±28.1 71.5±29.5 0.36 0.28 Change in Angulation, degrees* 25.2±18.8 31.9±26.4 15.5±19.2 19.7±21.3 0.01 Curvature Difference (mm-1)* 0.08±0.08 0.06±0.06 0.05±0.05 0.10 0.20 Single Stents Only N=41 N=48 17.2±5.4 21.5±7.1 0.002 78.8±13.6 78.9±11.8 0.98 80.6±23.1 94.6±25.1 75.4±24.2 90.8±26.3 0.30 0.49 56.0±27.5 64.7±29.6 60.5±28.7 71.7±30.10 0.45 0.27 24.7±18.4  30.0±23.5 14.9±19.2 19.1±21.5 0.02 0.03 0.08±0.07 0.06±0.07 0.04±0.05 0.23 0.29 Maximum Minimum Pre-procedure Post-procedure Pre-procedure Post-procedure Curvature Angulation Both A and B were chosen based on the degree of baseline bend and are from the CoCr-EES arm Summary and Conclusion In highly angulated lesions, unplanned stenting was more frequently required with CoCr-EES compared to PtCR-EES. Vessel straightening, as measured by the change in angulation before and after stenting, was greater with CoCr-EES both overall and when the analysis was restricted to patients who received a single stent. The clinical implications of this finding warrant further study. This study was supported by Boston Scientific (BSC). Disclosures: JJP –Research Grants and Medical Advisory Board for BSC; AA – None; DJK – Grants/Research Support from BSC, Abbott Vascular and Medtronic, Consultant for BSC, Abbott Vascular and REVA Medical; ITM –SAB and consultant proctor for BSC; PST – Consultant Abbott Vascular and BSC; DJA – full-time employee and stockholder of BSC, KDD - full-time employee and stockholder of BSC, GWS – Consultant BSC *Change in angulation and curvature differences were calculated as pre-procedure – post-procedure